Last reviewed · How we verify
SYS6006
At a glance
| Generic name | SYS6006 |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults. (PHASE1)
- A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More (PHASE2)
- A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years. (PHASE1)
- Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults (PHASE4)
- The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |